Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cyclophosphamide induces differentiation of Th17 cells in cancer patients.
Viaud S, Flament C, Zoubir M, Pautier P, LeCesne A, Ribrag V, Soria JC, Marty V, Vielh P, Robert C, Chaput N, Zitvogel L. Viaud S, et al. Among authors: chaput n. Cancer Res. 2011 Feb 1;71(3):661-5. doi: 10.1158/0008-5472.CAN-10-1259. Epub 2010 Dec 9. Cancer Res. 2011. PMID: 21148486 Clinical Trial.
IL-18 induces PD-1-dependent immunosuppression in cancer.
Terme M, Ullrich E, Aymeric L, Meinhardt K, Desbois M, Delahaye N, Viaud S, Ryffel B, Yagita H, Kaplanski G, Prévost-Blondel A, Kato M, Schultze JL, Tartour E, Kroemer G, Chaput N, Zitvogel L. Terme M, et al. Among authors: chaput n. Cancer Res. 2011 Aug 15;71(16):5393-9. doi: 10.1158/0008-5472.CAN-11-0993. Epub 2011 Jul 1. Cancer Res. 2011. PMID: 21724589
Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells.
Terme M, Ullrich E, Aymeric L, Meinhardt K, Coudert JD, Desbois M, Ghiringhelli F, Viaud S, Ryffel B, Yagita H, Chen L, Mécheri S, Kaplanski G, Prévost-Blondel A, Kato M, Schultze JL, Tartour E, Kroemer G, Degli-Esposti M, Chaput N, Zitvogel L. Terme M, et al. Among authors: chaput n. Cancer Res. 2012 Jun 1;72(11):2757-67. doi: 10.1158/0008-5472.CAN-11-3379. Epub 2012 Mar 16. Cancer Res. 2012. PMID: 22427351
Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.
Pautier P, Locher C, Robert C, Deroussent A, Flament C, Le Cesne A, Rey A, Bahleda R, Ribrag V, Soria JC, Vassal G, Eggermont A, Zitvogel L, Chaput N, Paci A. Pautier P, et al. Among authors: chaput n. Oncoimmunology. 2013 Feb 1;2(2):e23079. doi: 10.4161/onci.23079. Oncoimmunology. 2013. PMID: 23525192 Free PMC article.
Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors.
Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, Vimond N, Concha A, Garrido F, Isambert N, Chaigneau L, Le Brun-Ly V, Dubreuil P, Cremer I, Caignard A, Poirier-Colame V, Chaba K, Flament C, Halama N, Jäger D, Eggermont A, Bonvalot S, Commo F, Terrier P, Opolon P, Emile JF, Coindre JM, Kroemer G, Chaput N, Le Cesne A, Blay JY, Zitvogel L. Rusakiewicz S, et al. Among authors: chaput n. Cancer Res. 2013 Jun 15;73(12):3499-510. doi: 10.1158/0008-5472.CAN-13-0371. Epub 2013 Apr 16. Cancer Res. 2013. PMID: 23592754
146 results